Literature DB >> 10469230

B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans.

C Monari1, T R Kozel, A Casadevall, D Pietrella, B Palazzetti, A Vecchiarelli.   

Abstract

The contribution of B7 molecules to the induction and maintenance of the T-cell response to the human pathogenic fungus Cryptococcus neoformans was investigated. T-cell activation by C. neoformans was regulated by B7 molecules. This costimulatory signal was necessary for initiation and maintenance of the T-cell response, through early and late requirements for B7-CD28 interaction. Blocking B7-2 inhibited the normal T-cell proliferative response. This inhibition was due, in part, to a reduced capability of T cells to produce interleukin-2 (IL-2). In contrast, the same T-cell population produced more interferon-gamma. Suppression of the normal lymphoproliferation and IL-2 secretion responses to encapsulated C. neoformans by antibodies to B7 was largely reversed by addition of the monoclonal antibody 2H1, that is reactive with the major capsular polysaccharide, glucuronoxylomannan. Overall, our data indicate that B7 molecules play a critical role in T-cell activation by C. neoformans and suggest that appropriate manipulation could drive T helper type 1 cell development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469230      PMCID: PMC2326901          DOI: 10.1046/j.1365-2567.1999.00853.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.

Authors:  V K Kuchroo; M P Das; J A Brown; A M Ranger; S S Zamvil; R A Sobel; H L Weiner; N Nabavi; L H Glimcher
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

Review 2.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors:  A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.

Authors:  M K Racke; D E Scott; L Quigley; G S Gray; R Abe; C H June; P J Perrin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

5.  Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection.

Authors:  A Vecchiarelli; M Dottorini; D Pietrella; C Monari; C Retini; T Todisco; F Bistoni
Journal:  Am J Respir Cell Mol Biol       Date:  1994-08       Impact factor: 6.914

6.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

7.  Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells.

Authors:  C P Larsen; S C Ritchie; R Hendrix; P S Linsley; K S Hathcock; R J Hodes; R P Lowry; T C Pearson
Journal:  J Immunol       Date:  1994-06-01       Impact factor: 5.422

8.  B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

Authors:  G J Freeman; V A Boussiotis; A Anumanthan; G M Bernstein; X Y Ke; P D Rennert; G S Gray; J G Gribben; L M Nadler
Journal:  Immunity       Date:  1995-05       Impact factor: 31.745

9.  Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages.

Authors:  A Vecchiarelli; D Pietrella; M Dottorini; C Monari; C Retini; T Todisco; F Bistoni
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

10.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

Authors:  D J Lenschow; S C Ho; H Sattar; L Rhee; G Gray; N Nabavi; K C Herold; J A Bluestone
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  6 in total

1.  A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide.

Authors:  M Piccioni; C Monari; S Bevilacqua; S Perito; F Bistoni; T R Kozel; A Vecchiarelli
Journal:  Clin Exp Immunol       Date:  2011-05-23       Impact factor: 4.330

2.  Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells.

Authors:  Anna Vecchiarelli; Donatella Pietrella; Francesco Bistoni; Thomas R Kozel; Arturo Casadevall
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

3.  Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses.

Authors:  Marta Feldmesser; Aron Mednick; Arturo Casadevall
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

4.  Cytotoxic T lymphocyte antigen costimulation influences T-cell activation in response to Cryptococcus neoformans.

Authors:  D Pietrella; S Perito; F Bistoni; A Vecchiarelli
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 5.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

6.  Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis.

Authors:  Claudia M L Maffei; Laurence F Mirels; Raymond A Sobel; Karl V Clemons; David A Stevens
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.